Advertisement

Topics

Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors

08:00 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
--Novel cancer vaccine encodes 20 neoepitopes on a single mRNA molecule to elicit a completely individualized immune response-- --Moderna and Merck collaborating to evaluate mRNA-4157 in combination with KEYTRUDA® (pem...

Other Sources for this Article

Moderna:
Media:
Liz Melone, 617-674-5648
liz.melone@modernatx.com
or
Investors:
Lorence Kim, 617-209-5849
lorence.kim@modernatx.com

NEXT ARTICLE

More From BioPortfolio on "Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...